CRC Research Update — October 29, 2026
Today's colorectal cancer research highlights
liver-mets
A collection of 85 issues
Liquid biopsy detects residual disease after oligometastasis surgery
Skip to content
The CRC Digest
▪ SCREENING
Liquid biopsy detects residual disease after oligometastasis surgery
A prospective multicenter study of 118 patients with resectable colorectal oligometastases found that combining pretreatment circulating tumor DNA genomic profiling with post-operative molecular residual disease (MRD) detection identified patients at highest risk of recurrence, with
CRC Research Update — October 14, 2026
Today's colorectal cancer research highlights
Recurrence drives long-term prognosis after liver metastasis resection
Skip to content
The CRC Digest
◆ TRIAL DATA
Recurrence drives long-term prognosis after liver metastasis resection
An international study of 3,002 patients who underwent hepatectomy for colorectal liver metastases found that 54% developed recurrence; multistate modeling showed that the probability of recurrence decreased the longer patients remained recurrence-free, and
CRC Research Update — October 13, 2026
Today's colorectal cancer research highlights
CRC Research Update — October 12, 2026
Today's colorectal cancer research highlights
CRC Research Update — October 11, 2026
Today's colorectal cancer research highlights
Liver metastases amplify immune resistance in MSS colorectal cancer
Skip to content
The CRC Digest
Liver metastases amplify immune resistance in MSS colorectal cancer
Across early-phase and retrospective studies, responses to checkpoint-based combinations have been observed more often in patients without active liver metastases in microsatellite-stable colorectal cancer. (Frontiers in Immunology)
This content is informational only and does not
CRC Research Update — October 10, 2026
Today's colorectal cancer research highlights
French trial tests reintroducing chemotherapy after liver metastasis resection
Skip to content
The CRC Digest
▸ TREATMENT
French trial tests reintroducing chemotherapy after liver metastasis resection
The IRIMAD phase III trial is randomizing patients who responded well to preoperative FOLFIRI and underwent curative resection of metachronous colorectal liver metastases to postoperative FOLFIRI reintroduction in the experimental arm. (Dig Liver Dis)